A cross-sectional study of privately insured patients with obesity showed that the use of GLP-1 RAs soared from 2022 to 2023, whereas the rates of metabolic bariatric surgery decreased.
The use of glucagon-like peptide 1 receptor agonists for obesity treatment increased more than twofold between the last half of 2022 and the last half of 2023, whereas the rate of metabolic bariatric surgery dropped by around 25% during the same period, suggesting a notable shift in obesity management strategies.
For each quarter, researchers identified patients with a claim for any formulation of semaglutide or liraglutide and for metabolic bariatric surgery and compared patient characteristics, including age, sex, and comorbidities. Only GLP-1 RA prescriptions with US Food and Drug Administration indications as anti-obesity medications were considered.
Patients undergoing metabolic bariatric surgery were more medically complex, with 18.8% having at least four comorbidities vs 8.2% of those who were prescribed GLP-1 RAs and 11.1% of those who received neither treatment .
Obesity Surgery Weight Loss Surgery Obesity Obese Surgery Metabolism Metabolic Practice Management Revenue Adherence Adherence To Medication Issues For Patients Compliance Drug Compliance Treatment Adherence Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks U.S. Food And Drug Administration
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
GLP-1 RAs Safe in the Perioperative Period: New GuidanceThe majority of patients may safely take glucagon-like peptide 1 receptor agonists before elective surgery and gastrointestinal endoscopies.
Read more »
Reassuring Data on GLP-1 RAs and Pancreatic Cancer RiskA new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.
Read more »
Bariatric Surgery Better Than Obesity Drugs for Some Patients With MASLDAlthough popular obesity medications appear promising, bariatric surgery may be better for certain patients with metabolic dysfunction–associated steatotic liver disease, new study results showed.
Read more »
To Hold or Not to Hold GLP-1s Before SurgeryDr Anne Peters discusses the conflicting recommendations from FDA and medical societies regarding managing patients on GLP-1s prior to elective surgery.
Read more »
How to Manage Patients on GLP-1s Before Surgery?An FDA label change and consensus guidance notwithstanding, endocrinologists seem to have made up their minds on how to handle patients on GLP-1s at high risk for aspiration.
Read more »
New Guidance for Patients Taking GLP-1 Drugs Before SurgeryAs the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new recommendations.
Read more »